(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 4.74% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Gilead Sciences's revenue in 2026 is $30,457,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,795,716,889,640, with the lowest GILD revenue forecast at $36,827,908,058,655, and the highest GILD revenue forecast at $40,598,611,685,010. On average, 32 Wall Street analysts forecast GILD's revenue for 2027 to be $41,296,706,437,275, with the lowest GILD revenue forecast at $38,663,041,688,055, and the highest GILD revenue forecast at $44,092,805,311,800.
In 2028, GILD is forecast to generate $43,296,754,102,290 in revenue, with the lowest revenue forecast at $39,165,223,525,830 and the highest revenue forecast at $49,319,216,290,125.